The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario

May 1, 2014, 00:00
10.1016/j.jval.2014.03.523
https://www.valueinhealthjournal.com/article/S1098-3015(14)00574-9/fulltext
Title : The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00574-9&doi=10.1016/j.jval.2014.03.523
First page : A90
Section Title : Cancer
Open access? : No
Section Order : 1580
Categories :
Tags :
Regions :
ViH Article Tags :